Personal information

No personal information available

Activities

Works (2)

Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A

Haemophilia
2021-01-24 | Journal article
Contributors: Midori Shima; Azusa Nagao; Masashi Taki; Tadashi Matsushita; Koichi Oshida; Kagehiro Amano; Sayaka Nagami; Norihiro Okada; Shingo Maisawa; Keiji Nogami
Source: check_circle
Crossref

A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors

Haemophilia
2019-11 | Journal article
Contributors: Midori Shima; Keiji Nogami; Sayaka Nagami; Seitaro Yoshida; Koichiro Yoneyama; Akira Ishiguro; Takashi Suzuki; Masashi Taki
Source: check_circle
Crossref